At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
orally-disintegrating olanzapine +1 moredrug
Likely dose
orally-disintegrating olanzapine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones
In Brief
A Phase 4 clinical trial evaluating orally-disintegrating olanzapine and regular olanzapine for Bipolar Depression. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This is an 8 week study that compares two medications. One medication is olanzapine (5-20 mg daily) whereas the other medication is an orally disintegrating medication. Both medications are used to treat depressed bipolar patients. The main focus of this study is the comparison of these two medications on gastro-intestinal hormones and weight gain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Depression
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartJan 2007
Primary CompletionMar 2010
TodayJul 2026
First PostedOct 6, 2006
Enrollment StartJan 1, 2007
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 19.7 years ago
Interventions
orally-disintegrating olanzapinedrug
5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
regular olanzapinedrug
5-20 mg. olanzapine daily for approximately 8 weeks.